[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345008-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345008-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","acquired-high-tumor-mutational-burden-and-activity-of-immunotherapy-after-targeted-therapy-in-microsatellite-stable-colorectal-cancer","Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer","","Microsatellite stable (MSS) colorectal cancers typically have few mutations and limited sensitivity to immune checkpoint blockade (ICB). Targeted agents used at progression can drive an increased number of genomic alterations, raising the question of whether they can produce high tumor mutational burden (TMB) and thereby sensitize MSS tumors to ICB. In MSS metastatic patients treated with targeted therapy, baseline and progression TMB and ICB response were assessed in cases developing acquired high TMB. Results showed high TMB emerging in nine of 26 cases, but no ICB responses, with no induction of tumor-infiltrating lymphocytes or PD-L1, and high TMB driven by subclonal alterations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/acquired-high-tumor-mutational-burden-and-activity-of-immunotherapy-after-targeted-therapy-in-microsatellite-stable-colorectal-cancer/345008/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/acquired-high-tumor-mutational-burden-and-activity-of-immunotherapy-after-targeted-therapy-in-microsatellite-stable-colorectal-cancer/345008.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main question of the study in MSS colorectal cancer?","Question",{"text":63,"@type":64},"Whether targeted therapy can induce a high tumor mutational burden (TMB) in microsatellite stable (MSS) colorectal cancer and sensitize these tumors to immune checkpoint blockade (ICB).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many MSS cases acquired high TMB at progression, and what was the ICB response?",{"text":68,"@type":64},"Among 26 cases, nine acquired high TMB at progression. Three patients received ICB, and none had a response.",{"name":70,"@type":61,"acceptedAnswer":71},"Why did acquired high TMB fail to translate into sensitization to ICB?",{"text":72,"@type":64},"The study found no induction of tumor-infiltrating lymphocytes or PD-L1 expression, and the genomic alterations were predominantly subclonal and inadequate to elicit a robust antitumor immune response.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345008,1790211541,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer  \nCeline Yeh1, Oliver Artz1, Haochen Zhang2,3, Elias-Ramzey Karnoub3,4, Peter Ntiamoah5, Caroline Weipert6, Henry Walch7,8, Emily Harrold1, Fergus Keane1, Sree Chalasani1, Neil H. Segal1,9, Michael B. Foote1,9, Andrea Cercek1,9, Andrew Pagano10, Steven B. Maron1,9, Luis A. Diaz Jr1,9, Christine A. Iacobuzio-Donahue3,4,5,9, Jinru Shia5,9, Benoit Rousseau1, and Rona Yaeger1,9  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Microsatellite stable (MSS) colorectal cancers, in contrast to microsatellite instability–high colorectal cancers, have few mutations and are insensitive to immune checkpoint blockade (ICB) . Colorectal cancers treated with targeted agents often acquire a high number of genomic alterations at progression. We asked whether targeted therapy could be used to generate a high tumor mutational burden (TMB) in MSS colorectal cancer and sensitize these tumors to ICB.\u003Cbr>Experimental Design: In patients with MSS metastatic colorectal cancer treated with targeted therapy, we evaluated baseline and progression TMB and response to ICB for patients whose tumors developed high TMB. We determined types of alterations, mutational signatures, neoantigenicity, and clonality associated with emergent genomic alterations in cases of acquired high TMB.\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Results: Among 26 cases, nine acquired high TMB at progression. Three of these patients received ICB but none had a response. In the TMB-high cases, we found no induction of tumor-infiltrating lymphocytes or PD-L1 expression. Acquired genomic alterations consisted predominantly of single-nucleotide variants, were enriched for single base substitution 17a/b mutational signature, and did not enhance predicted MHC class I binding. TMB was higher in plasma, driven by highly subclonal acquired alterations, compared with tissue samples, which harbored few resistance alterations.\u003Cbr>Conclusions: A substantial number of MSS colorectal cancers acquire high TMB following targeted therapy. However, this change is not associated with sensitization to ICB. The high TMB is due to subclonal alterations unique to individual disease sites that are inadequate to elicit a robust antitumor immune response.\u003Cbr>See related commentary by Parseghian and Eluri, p. 999 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nImmune checkpoint blockade (ICB) has transformed clinical outcomes and is now standard of care for patients with advanced,  \n1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York. 3Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. 4David","cbCaiubiajOqo8KA","https://ap.wps.com/l/cbCaiubiajOqo8KA","pdf",11636729,"English","# Purpose\n## Experimental Design\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the main question of the study in MSS colorectal cancer?\",\"answer\":\"Whether targeted therapy can induce a high tumor mutational burden (TMB) in microsatellite stable (MSS) colorectal cancer and sensitize these tumors to immune checkpoint blockade (ICB).\"},{\"question\":\"How many MSS cases acquired high TMB at progression, and what was the ICB response?\",\"answer\":\"Among 26 cases, nine acquired high TMB at progression. Three patients received ICB, and none had a response.\"},{\"question\":\"Why did acquired high TMB fail to translate into sensitization to ICB?\",\"answer\":\"The study found no induction of tumor-infiltrating lymphocytes or PD-L1 expression, and the genomic alterations were predominantly subclonal and inadequate to elicit a robust antitumor immune response.\"}]","Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer | PDF",1790056185,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/601003d10a58578bf6ca1a63b7a87cc6.webp",983,1315,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd07cb16a897af2a41655f8ccd96d4c2.webp",982,1314,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f4601af6983160fb535201886211235.webp",981,1312,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59b53ddff9eaccadd035b1a1d1038f60.webp",980,1311]